on behalf of the CREDO-Kyoto PCI/ CABG Registry Cohort-2 Investigators Background-Optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has not been yet fully elucidated. Methods and Results-We assessed the influence of prolonged thienopyridine therapy on clinical outcomes with landmark analysis at 4 and 13 months after DES implantation. Among 6802 patients with at least 1 DES implantation in the CREDO-Kyoto Registry Cohort-2, 6309 patients (on thienopyridine, 5438 patients; off thienopyridine, 871 patients) and 5901 patients (on thienopyridine, 4098 patients; off thienopyridine, 1803 patients) were eligible for the 4-and 13-month landmark analyses, respectively. The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine. Patients taking thienopyridine had more complex comorbidities and more complex lesion and procedural characteristics as compared with patients not taking thienopyridine. After adjusting for confounders, thienopyridine use was not associated with decreased risk for death/myocardial infarction/stroke (hazard ratio [HR], 1.13; 95% confidence interval [CI], 0.89 -1.43, Pϭ0.32 in the 4-month landmark analysis; HR, 1.14; 95% CI, 0.90 -1.45, Pϭ0.29 in the 13-month landmark analysis, respectively), whereas the risk for GUSTO moderate/severe bleeding tended to be higher in patients taking thienopyridine (HR, 1.51; 95% CI, 1.00 -2.23, Pϭ0.049 in the 4-month landmark analysis; HR, 1.44; 95% CI, 0.99 -2.09, Pϭ0.057 in the 13-month landmark analysis, respectively). Conclusions-Prolonged thienopyridine therapy beyond 4 and 13 months appeared not to be associated with reduction in ischemic events but to be associated with a trend toward increased bleeding. Optimal duration of DAPT after DES implantation might be shorter than the currently recommended 1-year interval. (Circ Cardiovasc Interv. 2012;5:381-391.)
C urrent guidelines recommend administration of dual antiplatelet therapy (DAPT) consisting of aspirin and thienopyridine for at least 1 year after coronary drug-eluting stent (DES) implantation. 1 Due to concerns about very late stent thrombosis (ST), extended use of thienopyridines beyond 1 year after DES implantation has become a common clinical practice. 2, 3 However, the optimal duration of DAPT after DES implantation has not yet been established. Recently, 2 randomized clinical trials demonstrated no difference in ischemic events between patients receiving aspirin plus clopidogrel and aspirin alone beyond either 1 year 4 or 6 months 5 after DES implantation. We previously reported the result of a 6-month landmark analysis based on the thienopyridine use, suggesting no apparent benefit of thienopyridine use beyond 6 months after sirolimus-eluting stents (SES) implantation. 3 Although the duration of DAPT in the early pivotal trials of SES and paclitaxel-eluting stents were only 2 to 3 months and 6 months, respectively, the incidence of late and very late ST in the DES arms were very low in these trials. 6, 7 Therefore, duration of DAPT shorter than the current recommendation might be appropriate after DES implantation. Furthermore, very few previous studies after DES implantation in real-world clinical practice evaluated the risk for bleeding events related to prolonged DAPT.
In an attempt to investigate the relation between duration of DAPT and clinical outcomes (both ischemic and bleeding events) after DES implantation, we conducted the 4-month and 13-month landmark analyses in a large observational database in Japan.
WHAT IS KNOWN
• Current guidelines recommend administration of dual antiplatelet therapy consisting of aspirin and thienopyridine for at least 1 year after coronary drug-eluting stent implantation.
WHAT THE STUDY ADDS
• The current study from CREDO-Kyoto Registry prolonged thienopyridine therapy was not associated with decreased risk for serious cardiovascular events, whereas it was associated with a trend toward an increased risk for bleeding in both 4-and 13-month landmark analyses.
• Discontinuation of both aspirin and thienopyridine therapy, but not discontinuation of thienopyridine therapy only, was associated with an increased risk of serious cardiovascular events and definite stent thrombosis within 1 year.
Methods

Study Population
The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in Kyoto) Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Grafting (CABG) Registry Cohort-2 is a physician-initiated, non-company-sponsored, multicenter registry enrolling consecutive patients undergoing first coronary revascu- The study design and patient enrollment of the CREDO-Kyoto PCI/CABG Registry Cohort-2 were previously described in detail. 2 Among 13 087 patients enrolled in the PCI arm of the registry, the study population for the current prespecified substudy consisted of 6802 patients (11142 treated lesions) who underwent at least 1 DES implantation (Figure 1) . SES was predominantly used (at least 1 SES use in 6325 patients [93%]). We assessed the relation between duration of thienopyridine therapy and clinical outcomes with so-called landmark analysis at 4 and 13 months after DES implantation. Eligible patients for the landmark analysis were those who were alive and free from death, myocardial infarction (MI), and stroke at the landmark point. Taking a 1-month window period into consideration, the 4-month and 13-month landmark points were selected because DAPT for at least 3 months is specified in the instruction for use of SES and because DAPT for at least 12 months after DES implantation is recommended in the current guideline.
Antiplatelet Therapy
The recommended antiplatelet therapy regimen was aspirin (Ն81 mg daily) indefinitely and thienopyridine (200 mg ticlopidine or 75 mg clopidogrel daily) for at least 3 months after DES implantation. The duration of DAPT was left to the discretion of each attending physician. Status of antiplatelet therapy during follow-up was also evaluated. Dates of discontinuation of aspirin and thienopyridine were reported separately during follow-up. If either aspirin or thienopyridine was restarted after discontinuation, the dates of restart were also recorded. Persistent discontinuation of thienopyridine was defined as withdrawal lasting at least 2 months. Those patients who discontinued persistently before the landmark points were classified into the group of patients "off thienopyridine." Those patients who had only temporary discontinuation of thienopyridine for less than 2 months were classified into the group of patients "on thienopyridine."
End Points
All the end points evaluated in this study were predefined. The primary outcome measure for ischemic events was a composite of death, MI, or stroke, whereas the primary outcome measure for bleeding events was defined as moderate or severe bleeding by Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) classification. 8 Individual components of the primary ischemic outcome measure were also evaluated. Definitions of other end points were described previously 2 (online-only Data Supplement Method A).
Data Collection and Follow-Up
Demographic, angiographic, and procedural data were collected from hospital charts or hospital databases according to prespecified definitions by experienced clinical research coordinators from the study management center (Research Institute for Production Development, Kyoto, Japan) (online-only Data Supplement Appendix B). Follow-up data were obtained from hospital charts or by contacting patients or referring physicians. Clinical events such as death, MI, ST, and bleeding were adjudicated by the clinical event committee (online-only Data Supplement Appendix C).
Median follow-up duration for surviving patients was 952 (first quartile to third quartile [Q1-Q3], 696 -1238) days. Complete 1-year follow-up information after the index stent implantation procedure was obtained in 6371 patients (93.7%) of 6802 study patients.
Statistical Analysis
Data are presented as values and percentages or mean value ϮSD or median and Q1-Q3. Categorical variables were compared with the 2 test or the Fisher exact test. Continuous variables were compared using the Student t test or Wilcoxon rank sum test, based on the distribution. Cumulative incidence was estimated by the KaplanMeier method, and differences were assessed with the log-rank test.
Landmark analyses were conducted as described previously. 9 We used the Cox proportional hazard model to estimate the risk of patients on thienopyridine at the 4-month and 13-month landmark points compared with patients off thienopyridine for long-term clinical events, adjusting the differences in baseline patient characteristics, procedural factors, medications, and center. Center was incorporated in the model as a stratification variable. In line with our previous report, we chose 39 clinically relevant factors shown in Table 1 as risk-adjusting variables. 2 The continuous variables were dichotomized by clinically meaningful reference values or median values. Proportional hazard assumption for the comparison between the patients on or off thienopyridine at the landmark points was assessed on the plots of log (time) versus log [-log (survival)] stratified by the thienopyridine use. The effects of thienopyridine use at the landmark points and other variables were expressed as hazard ratio (HR) and their 95% confidence intervals (CI).
In an attempt to complement the landmark analysis, we conducted an additional sensitivity analysis evaluating unadjusted event rates according to the status of aspirin therapy and thienopyridine therapy during the 3 time intervals after index PCI (within 30 days, 31-120 days, and 121-365 days). Patients with known discontinuation of therapy for any duration until the end of the given intervals were assigned to the discontinuation group in this analysis.
All analyses were conducted by 2 physicians (Drs Tada and Natsuaki) and a statistician (Dr Morimoto) with the use of SAS 9.2 and JMP 7.0 (SAS Institute Inc, Cary, NC). All the statistical analyses were 2-tailed, and probability values Ͻ0.05 were considered statistically significant.
Results
Landmark Analysis at 4 Months
Cumulative incidence of persistent discontinuation of thienopyridine was 14% at 4 months, 31% at 13 months, and 44% at 3 years after DES implantation (Figure 2 ). Among 6309 patients eligible for the 4-month landmark analysis, 5438 patients (86%) were maintained on thienopyridine at the 4-month landmark point (median duration of thienopyridine use [Q1-Q3], 838 days [418 -1133]), whereas 871 patients (14%) had discontinued thienopyridine before the 4-month landmark point (65 days [27-93]) ( Figure 1 ). Among 871 patients in the "off thienopyridine" group, 216 (25%) patients received thienopyridine therapy again after the landmark point, whereas 1846 (34%) of 5438 patients in the "on thienopyridine" group discontinued thienopyridine after the landmark point (online-only Data Supplement Results). Patients on thienopyridine as compared with patients off thienopyridine more often had more complex comorbidities and lesion characteristics (Table 1) .
At 3 years after initial DES implantation, cumulative incidence of the primary outcome measure for ischemic events (death/MI/stroke) was not different between the 2 groups of patients on and off thienopyridine at 4 months (9.5% versus 8.9%, Pϭ0.49) ( Table 2 and Figure 3A ). After adjusting for confounders, thienopyridine use as compared with no thienopyridine use at the 4-month landmark was associated with similar risk for death/MI/stroke (HR, 1.13; 95% CI, 0.89 -1.43, Pϭ0.32). Adjusted risks for individual components of the primary ischemic end point in patients on thienopyridine as compared with patients off thienopyridine at 4 months were as follows: HR, 1.15; 95% CI, 0.83 to 1.57, Pϭ0.40 for all-cause death; HR, 0.93; 95% CI, 0.53 to 1.61, Pϭ0.79 for MI; and HR, 1.23; 95% CI, 0.79 to 1.91, Pϭ0.37 for stroke. Cumulative incidence of definite ST tended to be lower in patients on thienopyridine than in patients off thienopyridine (0.4% versus 0.8%, Pϭ0.052) ( Table 2 ). Cumulative incidence of the primary outcome measure for bleeding (GUSTO moderate/severe bleeding) was significantly higher in patients on thienopyridine than in patients off thienopyridine at 4 months (4.2% versus 3.0%, Pϭ0.04) ( Table 2 and Figure 3B ). After adjusting for confounders, the risk of thienopyridine use relative to no thienopyridine use at the 4-month landmark for bleeding remained significant (HR, 1.51; 95% CI, 1.00 -2.23, Pϭ0.049).
Landmark Analysis at 13 Months
Among 5901 patients eligible for the 13-month landmark analysis, 4098 patients (69%) were maintained on thienopyri- (Figure 1 ). Among 1803 patients in the "off thienopyridine" group, 289 (16%) patients received thienopyridine therapy again after the landmark point, whereas 788 (19%) of 4098 patients in the "on thienopyridine" group discontinued thienopyridine after the landmark point (online-only Data Supplement Results). The differences in baseline characteristics and medications between the 2 groups of patients on and off thienopyridine at 13 months were generally consistent with those found in the 4-month landmark analysis (Table 3) . Three-year clinical outcomes in the 13-month landmark analysis were consistent with those in the 4-month landmark analysis. Cumulative incidence of death/MI/stroke was not different between the 2 groups of patients on and off thienopyridine at 13 months (6.9% versus 6.3%, Pϭ0.42) ( Table 4 and Figure 4A ). Cumulative incidence of stroke, ischemic stroke in particular, was significantly higher in patients on thienopyridine than in patients off thienopyridine at 13 months (2.8% versus 1.7%, Pϭ0.007, and 2.1% versus 1.3%, Pϭ0.04, respectively), whereas cumulative incidence of hemorrhagic stroke was not different between the 2 groups (0.6% versus 0.5%, Pϭ0.17) ( Table 4) . After adjusting for confounders, thienopyridine use as compared with no thienopyridine use at the 13-month landmark was associated with similar risk for death/MI/stroke (HR, 1.14; 95% CI, 0.90 -1.45, Pϭ0.29). Adjusted risks for individual components of the primary ischemic end point in patients on thienopyridine as compared with patients off thienopyridine at 13 months were as follows: HR, 1.20; 95% CI, 0.88 to 1.64, Pϭ0.25 for all-cause death; HR, 0.78; 95% CI, 0.44 to 1.36, Pϭ0.38 for MI; and HR, 1.58; 95% CI, 1.01 to 2.48, Pϭ0.045 for stroke. Cumulative incidence of definite ST tended to be lower in patients on thienopyridine than in patients off thienopyridine (0.2% versus 0.6%, Pϭ0.051).
Cumulative incidence of bleeding was significantly higher in patients on thienopyridine than in patients off thienopyridine at 13 months (2.8% versus 2.4%, Pϭ0.04) ( Table 4 and Figure 4B ). After adjusting for confounders, thienopyridine use as compared with no thienopyridine use at the 13-month landmark was associated with a statistically insignificant trend for greater risk of bleeding (HR, 1.44; 95% CI, 0.99 -2.09, Pϭ0.057).
Incidence of Ischemic Cardiovascular Events According to Status of Antiplatelet Therapy
Patients who discontinued both aspirin and thienopyridine had a significantly higher rate of death/MI/stroke than those who continued both agents in the intervals of 0 to 30 days, 31 to 120 days, and 121 to 365 days after stent implantation ( Figure 5A ). Regarding ST, patients who discontinued both aspirin and thienopyridine had a significantly higher rate than those who continued both agents in the interval of 31 to 120 days after stent implantation and had a trend toward higher rate in the interval of 121 to 365 days ( Figure 5B ). However, patients who discontinued thienopyridine only had similar rates of death/MI/stroke and definite ST as compared with patients who continued both aspirin and thienopyridine in any time intervals after stent implantation. Adjustment for covariates with multivariate model on this sensitivity analysis was conducted and yielded similar results as the unadjusted analysis (data not shown).
Regarding timing of events after antiplatelet therapy discontinuation, almost half of the serious cardiovascular events in patients who discontinued both aspirin and thienopyridine occurred within 14 days after discontinuation, and 79% of events occurred within 1 year, whereas event rates increased more gradually in patients who discontinued thienopyridine only ( Figure 6A and 6B). Academic Research Consortium definite ST occurred predominantly within 6 months after discontinuation in patients who discontinued both agents, whereas definite ST occurred more constantly through 3 years in patients who discontinued thienopyridine only (Figure 6C and 6D ).
Discussion
The main findings of the current study are the following: (1) Prolonged thienopyridine therapy after DES implantation either beyond 4 or 13 months appeared not to be associated with lower risk for serious cardiovascular events, whereas it was associated with a trend toward an increased risk of bleeding in both 4-month and 13-month landmark analyses; and (2) discontinuation of both aspirin and thienopyridine therapy, but not discontinuation of thienopyridine therapy only, was associated with an increased risk of serious cardiovascular events and definite ST within 1 year.
Previous cohort studies demonstrated that definite ST continued to occur at the constant rate of 0.2% to 0.6% per year after 30 days up to 2 to 3 years after DES implantation. 3, 10 Premature discontinuation of antiplatelet therapy is reported to be the most powerful predictor of ST and adverse cardiovascular outcomes after DES implantation. 11, 12 Due to concerns on very late ST, extended use of thienopyridines BMI indicates body mass index; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; LAD, left anterior descending coronary artery; LMCA, left main coronary artery; CTO, chronic total occlusion; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and H2-blocker, histamine type 2 receptor blocker.
Data on missing values are indicated in the online-only Data Supplement Methods (C). beyond 1 year after DES implantation has become a common clinical practice. 2, 3 However, reports from observational studies were discordant in terms of the benefits of prolonged DAPT; some small studies suggested benefit from extended DAPT even beyond 12 months after DES implantation, 9, 13 whereas others suggested no benefit beyond 6 months after DES implantations. 3, 11, 14 Several randomized, controlled trials are currently ongoing to define optimal duration of DAPT after coronary DES implantation. To date, 2 completed report from these randomized, controlled trials was published, suggesting no benefit for extended DAPT beyond either 12 months 4 or 6 months. 5 Consistent with these randomized trials, DAPT beyond 13 months after DES implantation was not associated with apparent clinical benefit in the current analysis. Regarding all the clinical end points assessed except for ST, the effect of prolonged DAPT was in the same direction. Although we found a small albeit statistically significant difference in the incidence of ST favoring prolonged DAPT, it was not translated into any meaningful reduction in cardiac death nor MI. Effect of long-term use of more aggressive antithrombotic therapy in patients undergoing PCI should be evaluated based not on reduction of ST but on reduction of overall cardiovascular events. The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and Avoidance study (CHARISMA) 14 could not demonstrate efficacy in reducing overall cardiovascular events with prolonged DAPT. Furthermore, it might be important to note that risk of stroke in the 13-month landmark analysis was significantly higher in patients on thienopyridine at 13 months than in patients not on thienopyridine. The higher risk of stroke in patients on thienopyridine at 13 months could be related to the greater prevalence of prior history of stroke. A trend for this unexpected increase in the risk of stroke with prolonged DAPT was also reported in REAL-LATE and ZEST-LATE trials but not in the CHARISMA trial. On-going, large-scale, randomized trials, such as DAPT and ISAR-SAFE, may provide definitive answers regarding the role of DAPT for extended period of time.
Furthermore, in the current analysis, the result of the 4-month landmark analysis was entirely consistent with the result of the 13-month landmark analysis. Therefore, duration of DAPT shorter than the current recommendation might be appropriate when the risk of bleeding overweigh the potential benefit of prolonged DAPT. Previous reports from randomized trials comparing long-term DAPT with single antiplatelet therapy consistently demonstrated higher rates of bleeding in patients treated with DAPT. 14 However, very few previous studies evaluated the risk of bleeding events related to prolonged DAPT in patients with DES implantation in real-world clinical practice. Current landmark analyses demonstrated small but significant increases in bleeding risk in patients receiving prolonged DAPT. Post-PCI bleeding is reported to be associated with worse prognosis. 15 Therefore, in deciding the duration of DAPT after stent implantation, the net benefits from prolonged antiplatelet therapy should be assessed after balancing the efficacy for reduction of thrombotic events and the safety regarding hemorrhagic risk.
Study Limitations
There are several important limitations in this study. First, the duration of thienopyridine therapy was left to the discretion of each attending physician and was not randomized. Despite extensive adjustment for potential confounding factors, we could not exclude the possibility for the presence of unmeasured confounding factors.
Second, landmark analysis has a possibility to underestimate the impact of thienopyridine discontinuation by excluding the events that occurred before landmark points. Furthermore, the 2-month window period for definition of persistent discontinuation of thienopyridine might cause overestimating the events in the group of patients on thienopyridine by counting the events that occurred during the window period. However, landmark analyses conducted as sensitivity analyses using 30-day duration criteria for persistent discontinuation of thienopyridine demonstrated consistent results as those using 2-month criteria for persistent discontinuation (data not shown). Furthermore, another sensitivity analysis including those patients with very short period of discontinuation clearly demonstrated that patients who discontinued thienopyridine only had similar rates of ischemic events as compared with patients who continued both aspirin and thienopyridine. Third, although data collection for the status of antiplatelet therapy was conducted throughout the follow-up periods, no attempt was made to verify compliance with antiplatelet medications for patients in whom discontinuation was not reported; this might well have led to overestimation of compliance. Also, when follow-up information was obtained by contact with patients, dates of discontinuation of thienopyridine were based on retrospective recall by the patients or their relatives, suggesting a potential for recall bias.
Fourth, CYP2C19 *2 or *3 mutations, which are known to be associated with diminished antiplatelet responses to clopidogrel, are more prevalent in Asians as compared with Western people. If overall antiplatelet response to DAPT was diminished in the current study population, the impact of discontinuation of thienopyridine might be attenuated in Asians as compared with that in Western people. Therefore, we should be cautious in extrapolating the current study result in Western people. Also, approximately 90% of thienopyridine was not clopidogrel but ticlopidine in the current study. Despite superior tolerability of clopidogrel as compared with ticlopidine, the efficacy in terms of preventing thrombotic events and the safety related to bleeding complications were comparable between these 2 thienopyridines. 16 Newer antiplatelet agents such as prasugrel and ticagrelor showed superior efficacy as compared with clopidogrel in terms of preventing serious cardiovascular events after coronary stenting at the collateral cost of higher bleeding risk. Therefore, the impact of discontinuation of these more potent antiplatelet agents might be different from the current study results. Furthermore, unfractionated heparin has been used in Japan instead of low-molecular-weight heparin, glycoprotein IIb/ IIIa inhibitors, or bivalirudin, which are not approved for use during and after PCI.
Fifth, in the current study, GUSTO classification was used as the bleeding definition, mainly because we thought that transfusion qualifying GUSTO moderate bleeding seemed to be an objective parameter, which could be collected more reliably in a retrospective study than the hemoglobin value at the time of suspected bleeding events. This is particularly true when the follow-up information was collected by contact with the patients. However, GUSTO classification might not be an appropriate definition for evaluating bleeding events during long-term follow-up after DES implantation because it was originally developed in evaluating bleeding events after thrombolytic therapy.
Finally, the limitation of the 4-month landmark analysis included the relatively small number of patients who had discontinued thienopyridine before the 4-month landmark point and a relatively large number of patients who discontinued thienopyridine after the 4-month landmark point.
Conclusions
Prolonged thienopyridine therapy after DES implantation appeared not to be associated with a risk reduction for serious cardiovascular events but was associated with a statistically insignificant trend toward increased risk for bleeding in a cohort of patients who had mostly stable coronary artery disease and in whom ticlopidine and SES was predominantly used under unfractionated heparin treatment. Optimal duration of DAPT after DES implantation might be shorter than currently recommended 1-year interval.
